Page 9 - Flipbook
P. 9
STAMPEDE: Radiotherapy to the Primary Tumour for mCSPC
OS by Metastatic Burden: Preplanned Subset Analysis
OS in low metastatic burden OS in high metastatic burden
100 100
Control
Radiotherapy 80
80
Overall Survival (%) 60 Overall Survival (%) 60
40
40
20 20
HR, 0.68 (95% CI, 0.52–0.90; p = 0.007 HR, 1.07 (95% CI, 0.90–1.28; p = 0.420
0 0
0 6 12 18 24 30 36 42 48 54 0 6 12 18 24 30 36 42 48 54
Time since randomization (months) Time since randomization (months)
No. at risk (events) No. at risk (events)
Control 409 (5) 400 (9) 387 (17) 361 (17) 265 (12) 217 (22) 155 (16) 110 (8) 67 (5) 25 567 (11) 547 (42) 500 (58) 428 (41) 312 (27) 245 (43) 161 (20) 100 (7) 48 (3) 13
Radiotherapy 410 (1) 405 (4) 399 (12) 366 (12) 301 (19) 242 (10) 200 (15) 137 (11) 77 (5) 25 553 (10) 537 (38) 487 (48) 424 (59) 282 (30) 216 (31) 146 (19) 90 (14) 44 (5) 20
Parker CC, et al. Lancet 2018;392:2353-2366.
